Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-3167 vs Insulin Glargine in Healthy Subjects
NCT07588906Phase 1Completed
- Sponsor
- Hengrui
- Start
- Feb 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-3167 in diabetes mellitus (DM), sponsored by Hengrui. Primary endpoint: Glucose infusion rate area under the curve. Started Feb 2024; status: completed.
02
Drugs
SHR-3167
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT07588906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07588906.